Phase I study of VRCTC-310, a purified phospholipase A2 purified from snake venom, in patients with refractory cancer: Safety and pharmacokinetic data

Anti-Cancer Drugs

Volumn 8, Issue 9, 1997, Pages 829-834

  Costa, Luis A ^a,b   Miles, Horacio A ^a   Diez, Roberta A ^c,d   Araujo, Carlos E ^a   Coni Molina, Carlos M ^a   Cervellino, Juan C ^a,c  

^a Hospital B Houssay   (Argentina)

^b Ventech Research Inc   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d NONE   (Argentina)

Author keywords

Anticancer therapy; Pharmacokinetics; Phase I; Phospholipase; Snake venom

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHOLIPASE A; SNAKE VENOM; UNCLASSIFIED DRUG; VRCTC 310;

ADULT; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIPLOPIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; EOSINOPHILIA; FEMALE; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PTOSIS; SOLID TUMOR; VISUAL IMPAIRMENT;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CROTOXIN; DIRECT LYTIC FACTORS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PHOSPHOLIPASES A; SNAKE VENOMS;

EID: 0030696873     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199710000-00003     Document Type: Article

References (9)

1. Newman RA, Vidal JC, Viskatis L, Johnson J, Etcheverry MA. VRCTC-310. A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity. Invest New Drugs 1993; 11: 151-9.
2. Hendon RA, Frankel-Conrat H. Biological roles of the two components of crotoxin. Proc Natl Acad Sci USA 1971: 68: 1560-3.
3. Harvey AL. Cardiotoxins from cobra venoms: possible mechanisms of action. J Toxicol Tox Res 1985: 4: 41-69.
4. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989; 81: 1088-92.
5. Habermann E, Breithaupt H. Mini-review. The crotoxin complex: an example of biochemical and pharmacological protein complementation. Toxicon 1978; 16: 19-30.
6. Common Toxicity Criteria. National Institute of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Bethesda 1993.
7. Shumaker RC. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17: 331-48.
8. Okamoto M, Viskatis LJ, De la Roza G, Vidal JC. Induction of tolerance to crotoxin in mice. J Pharmacol Exp Ther 1993; 265: 41-6.
9. Chabner BA, Allegra CJ, Curt GA, Calabressi P. L-asparaginasa. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Las bases farmacológicas de la terapéutica de Goodman & Gilman, 9th edn. México: McGraw-Hill-Interamericana 1996: 1348-50.